| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study |
Rejected |
BRENTUXIMAB VEDOTIN |
3 |
RJ19/119/J |
King Abdulaziz Medical City NG (Riyadh) |
| The effect of (Oligonol) and (Oligonol + metformin) on the components of Metabolic Syndrome in obese individuals- A randomized, double-blind, factorial clinical trial. |
Terminated |
Oligonol |
3 |
SDRG- Amino Up 1 |
KFMRC-J |
| "An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure " |
Completed |
Dapagliflozin |
3 |
D169CC00001 |
KKUH |
| Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide |
Ongoing |
Talquetamab |
3 |
80202135EBF3001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| A Prospective, Multicenter, Single-Arm, Open-Label, Phase 3 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging. (RESTORE) |
Completed |
Selexipag |
3 |
67896049PAH4005 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING BLEEDING INCIDENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS AND NON-INHIBITORS TREATED WITH EMICIZUMAB AND OTHER HEMOPHILIA TREATMENTS IN A REAL-LIFE SETTING |
Ongoing |
emicizumab |
4 |
MO401001 |
King Abdulaziz Medical City NG (Jeddah) |
| A 24-week, multicentre, non-interventional, prospective study to describe clinical outcomes of advancing therapy with iGlarLixi in patients with T2DM sub-optimally controlled on basal insulin with or without OADs in daily practice in Saudi Arabia |
Ongoing |
iGlarLixi |
4 |
OBS17984 |
King Fahad Medical City (Riyadh),King Fahad Specialist Hospital, Buraydah, Hira Hospital (Makkah) ,Al-AlSheikh Diabetes Cente (Riyadh) |
| REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immunooncology immune checkpoint inhibitor combination in first-line. |
Ongoing |
ATC L01XE21, Protein kinase inhibitors, Regorafenib, Sorafenib, |
4 |
22453 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study |
Rejected |
BRENTUXIMAB VEDOTIN , DOXORUBICIN HYDROCHLORIDE , VINBLASTINE SULPHATE , Dacarbazine |
2 |
RJ19/119/J |
King Abdulaziz Medical City NG (Jeddah) |
| A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1 |
Ongoing |
Hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) |
3 |
CTD-TCNPC-301 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
